What does this research mean for the field?

Remimazolam provides rapid recovery and has a low rate of serious adverse events when used for procedural sedation and anesthesia across diverse clinical settings and patient acuities. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the patterns of remimazolam use and recovery characteristics in a multicenter cohort.

July 5, 2026BJA OpenOpen Access

Patterns of remimazolam use and recovery after procedural sedation and anaesthesia: a multicentre cohort study

View Full Paper

Ask AI

Bookmark

Authors

AGAbhinav Goyal DSDarrell R. Schroeder AAArnoley S. Abcejo

Discussion

Member takes

Overview

Retrospective cohort study highlights rapid recovery with remimazolam in diverse procedural environments, suggesting safety and efficacy.

Key Points

To investigate the patterns of remimazolam use and recovery characteristics in a multicenter cohort.
Retrospective cohort study of patients receiving remimazolam from US academic health systems.
Assessment of primary outcomes, including recovery times and flumazenil usage.
Linear mixed models were employed to analyze associations with reported geometric mean ratios.
Median time to baseline Richmond Agitation–Sedation Scale was 13 min (IQR 5–30).
Median PACU discharge readiness time was 30 min (IQR 15–55).
Critical events occurred in only 0.7% of procedures, including 0.04% possible IgE-mediated reactions.

Cite This Study

Goyal et al. (2026) studied this question.

synapsesocial.com/papers/6a49f411f5d1d45b287ffbb0 https://doi.org/10.1016/j.bjao.2026.100575

View Full Paper

Ask AI

Bookmark

July 5, 2026BJA OpenOpen Access

Patterns of remimazolam use and recovery after procedural sedation and anaesthesia: a multicentre cohort study

View Full Paper

Ask AI

Bookmark

Authors

AGAbhinav Goyal DSDarrell R. Schroeder AAArnoley S. Abcejo

Discussion

Member takes

Overview

Retrospective cohort study highlights rapid recovery with remimazolam in diverse procedural environments, suggesting safety and efficacy.

Key Points

To investigate the patterns of remimazolam use and recovery characteristics in a multicenter cohort.
Retrospective cohort study of patients receiving remimazolam from US academic health systems.
Assessment of primary outcomes, including recovery times and flumazenil usage.
Linear mixed models were employed to analyze associations with reported geometric mean ratios.
Median time to baseline Richmond Agitation–Sedation Scale was 13 min (IQR 5–30).
Median PACU discharge readiness time was 30 min (IQR 15–55).
Critical events occurred in only 0.7% of procedures, including 0.04% possible IgE-mediated reactions.

Cite This Study

Goyal et al. (2026) studied this question.

synapsesocial.com/papers/6a49f411f5d1d45b287ffbb0 https://doi.org/10.1016/j.bjao.2026.100575

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark